NRx Pharmaceuticals NRXP is expected to report its fourth-quarter 2024 results soon. The Zacks Consensus Estimate for NRXP’s ...

Treatment-resistant depression complicates care, defying standard treatments, but new therapies are on the horizon, offering hope for more effective treatment options.

Jason Najum talks to Srinivas Rao, CEO of Atai Life Sciences, a biotech company focused on mental health and psychedelic compounds.

Stella Mental Health Westmont is a top depression and anxiety clinic near Chicago that offers comprehensive mental health treatments like Spravato (esketamine) therapy, ketamine infusion ...

Ketamine has long been seen as a potential ... who have cycled through multiple treatments without relief. Spravato (esketamine) has been touted as a potential blockbuster for Janssen, which ...

Stifel has initiated Compass Pathways (NASDAQ:CMPS) with a buy rating saying that stakeholders are starting to agree there is ...